Antimicrobial susceptibility of clinically relevant gram-positive anaerobic cocci collected over a three-year period in the Netherlands

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1199-1203

  Veloo, A C M ^a   Welling, G W ^a   Degener, J E ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTETAN; CEFOXITIN; CHLORAMPHENICOL; CLINDAMYCIN; DOXYCYCLINE; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; TIGECYCLINE;

ANAEROCOCCUS MURDOCHII; ANAEROCOCCUS VAGINALIS; ANTIBIOTIC SENSITIVITY; ARTICLE; FINEGOLDIA MAGNA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; GRAM POSITIVE ANAEROBIC COCCI; GRAM POSITIVE COCCI; MINIMUM INHIBITORY CONCENTRATION; NETHERLANDS; NONHUMAN; PARVIMONAS MICRA; PEPTONIPHILUS GORBACHII; PEPTONIPHILUS HAREI; PEPTOSTREPTOCOCCUS ANAEROBIUS; PRIORITY JOURNAL; SYSTOLIC HEART FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; GRAM-POSITIVE COCCI; MICROBIAL SENSITIVITY TESTS; NETHERLANDS;

EID: 79952355754     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01771-09     Document Type: Article

References (22)

1. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
2. Boom, R., et al. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
3. Bowker, K. E., M. Wootton, H. A. Holt, D. S. Reeves, and A. P. MacGowan. 1996. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria. J. Antimicrob. Chemother. 38:271-281.
4. Brazier, J., et al. 2008. European surveillance study on antimicrobial susceptibility of Gram-positive anaerobic cocci. Int. J. Antimicrob. Agents 31:316-320.
5. Brazier, J. S., W. Hall, T. E. Morris, M. Gal, and B. I. Duerden. 2003. Antibiotic susceptibilities of Gram-positive anaerobic cocci: results of a sentinel study in England and Wales. J. Antimicrob. Chemother. 52:224-228.
6. Downes, J., and W. G. Wade. 2006. Peptostreptococcus stomatis sp. nov., isolated from the human oral cavity. Int. J. Syst. Evol. Microbiol. 56:751-754.
7. Ezaki, T., et al. 2001. Proposal of the genera Anaerococcus gen. nov., Peptoniphilus gen. nov., and Gallicola gen. nov. for members of the genus Peptostreptococcus. Int. J. Syst. Evol. Microbiol. 51:1521-1528.
8. Goto, T., et al. 2008. Complete genome sequence of Finegoldia magna, an anaerobic opportunistic pathogen. DNA Res. 15:39-47.
9. Hiraishi, A. 1992. Direct automated sequencing of 16S rDNA amplified by polymerase chain reaction from bacterial cultures without DNA purification. Lett. Appl. Microbiol. 15:210-213.
10. Jousimies-Somer, H. R., et al. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing, Belmont, CA.
11. Koeth, L. M., et al. 2004. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J. Antimicrob. Chemother. 53:1039-1044.
12. Könönen, E., A. Bryk, P. Niemi, and A. Kanervo-Nordström. 2007. Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources. Antimicrob. Agents Chemother. 51:2205-2207.
13. Liu, C.-Y. Y.-T. Huang, C.-H. Liao, L.-C. Yen, H.-Y. Lin, and P.-R. Hsueh. 2008. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob. Agents Chemother. 52:3161-3168.
14. Murdoch, D. A., I. J. Mitchelmore, and S. Tabaqchali. 1994. The clinical importance of gram positive anaerobic cocci isolated at St. Bartholomew's hospital, London, in 1987. J. Med. Microbiol. 41:36-43.
15. Murdoch, D. A., and H. N. Shah. 1999. Reclassification of Peptostreptococcus magnus (Prevot 1933) Holdeman and Moore 1972 as Finegoldia magna comb. nov. and Peptostreptococcus micros (Prevot 1933) Smith 1957 as Micromonas micros comb. nov. Anaerobe 5:555-559.
16. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1993. Susceptibilities of 428 Gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob. Agents Chemother. 37:1649-1654.
17. Reference deleted.
18. Roberts, S. A., K. P. Shore, S. D. Paviour, D. Holland, and A. J. Morris. 2006. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003. J. Antimicrob. Chemother. 57:992-998.
19. Song, Y., C. Liu, and S. M. Finegold. 2007. Peptoniphilus gorbachii sp. nov., Peptoniphilus olsenii sp. nov., and Anaerococcus murdochii sp. nov. isolated from clinical specimens of human origin. J. Clin. Microbiol. 45:1746-1752.
20. Tindall, B. J., and J. P. Euzéby. 2006. Proposal of Parvimonas gen. nov. and Quatrionicoccus gen. nov. as replacements for the illegitimate, prokaryotic, generic names Micromonas Murdoch and Shah 2000 and Quadricoccus Maszenan et al. 2002, respectively. Int. J. Syst. Evol. Microbiol. 56:2711-2713.
21. Wildeboer-Veloo, A. C. M., H. J. M. Harmsen, G. W. Welling, and J. E. Degener. 2007. Development of 16S rRNA-based probes for the identification of Gram-positive anaerobic cocci isolated from human clinical specimens. Clin. Microbiol. Infect. 13:985-992.
22. Wren, M. W. D. 1996. Anaerobic cocci of clinical importance. Br. J. Biomed. Sci. 53:294-301.